Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Provided is a compound of Chemical Formula 1: ##STR00001## where A and B each independently is a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic or dicyclic heteroaryl group, a substituted or unsubstituted dibenzofuran group, a substituted or unsubstituted benzonaphthofuran group, a substituted or unsubstituted dibenzothiophene group, a substituted or unsubstituted benzonaphthothiophene group, a substituted or unsubstituted phenoxazine group, a substituted or unsubstituted phenothiazine group, a substituted or unsubstituted phenanthroline group, a substituted or unsubstituted benzoquinoline group, a substituted or unsubstituted arylamine group, a substituted or unsubstituted silyl group, or a substituted or unsubstituted phosphine oxide group, or one of the following substituents: ##STR00002## and an organic light emitting device including the same.

Provided is a compound of Chemical Formula 1: ##STR00001## where A and B each independently is a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic or dicyclic heteroaryl group, a substituted or unsubstituted dibenzofuran group, a substituted or unsubstituted benzonaphthofuran group, a substituted or unsubstituted dibenzothiophene group, a substituted or unsubstituted benzonaphthothiophene group, a substituted or unsubstituted phenoxazine group, a substituted or unsubstituted phenothiazine group, a substituted or unsubstituted phenanthroline group, a substituted or unsubstituted benzoquinoline group, a substituted or unsubstituted arylamine group, a substituted or unsubstituted silyl group, or a substituted or unsubstituted phosphine oxide group, or one of the following substituents: ##STR00002## and an organic light emitting device including the same.

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Electrolytes and electrolyte additives for energy storage devices comprising functional thiophene compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte, and at least one electrolyte additive selected from a thiophene compound.

Electrolytes and electrolyte additives for energy storage devices comprising functional thiophene compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte, and at least one electrolyte additive selected from a thiophene compound.

Provided are an organic electric element comprising as a phosphorescent host material, a mixture of the compounds of Formula (1) and Formula (2), and an organic electronic device or apparatus thereof for achieving a high luminous efficiency, a low driving voltage, and an improved lifespan.

Provided are an organic electric element comprising as a phosphorescent host material, a mixture of the compounds of Formula (1) and Formula (2), and an organic electronic device or apparatus thereof for achieving a high luminous efficiency, a low driving voltage, and an improved lifespan.

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).